

## Literaturverzeichnis

Hamburger Ärzteblatt 09 | 2021

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: [verlag@aekhh.de](mailto:verlag@aekhh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

### S. 20 – 22: Die gesundheitliche Situation von wohnungslosen Menschen.

Von Franziska Bertram, Victoria van R  th, Prof. Dr. Klaus P  schel, Prof. Dr. Benjamin Ondruschka, PD Dr. Birgit Wulff, Fabian Heinrich

1. Neupert P, Lotties S. Statistikbericht: Zur Lebenssituation von Menschen in den Einrichtungen und Diensten der Hilfen in Wohnungsnotfallen in Hamburg, 2018. [Statistics on the situation of people with sheltering emergencies in public accomodations and support programm]. Retrieved February 5, 2021, from [https://www.bagw.de/de/themen/statistik\\_und\\_dokumentation/statistikberichte/index.html](https://www.bagw.de/de/themen/statistik_und_dokumentation/statistikberichte/index.html)
2. Ratzka M, Kamper A. Befragung obdachloser, auf der Stra e lebender Menschen und wohnungsloser,  ffentlich-rechtlich untergebrachter Haushalte 2018 in Hamburg. Auswertungsbericht [Survey of homeless individuals living on the street or in public housing in 2018 in Hamburg]. Retrieved February 5, 2021, from <https://www.hamburg.de/contentblob/12065738/5702405ed386891a25cdf9d4001e546b/data/d-obdachlosenstudie-2018.pdf>
3. Fazel S., Geddes JR, Kushel M. The health of homeless people in high-income countries: Descriptive epidemiology, health consequences, and clinical and policy recommendations. *The Lancet* 2014; 384(9953), 1529–1540. [https://doi.org/10.1016/S0140-6736\(14\)61132-6](https://doi.org/10.1016/S0140-6736(14)61132-6)
4. Grabs J, Ishorst-Witte F, P  schel K. Todesursachen wohnungsloser Menschen in Hamburg. „Krank bin ich, wenn nichts mehr geht“. *Hamburger rzteblatt*, Ausgabe 5, 2008; 6–8.
5. Tsai J, Wilson M. COVID-19: a potential public health problem for homeless populations. *The Lancet Public Health* 2020; 5(4), e186–e187. [https://doi.org/10.1016/s2468-2667\(20\)30053-0](https://doi.org/10.1016/s2468-2667(20)30053-0)
6. Wood LJ, Davies AP, Khan Z. COVID-19 precautions: easier said than done when patients are homeless. *Medical Journal of Australia* 2020; 212(8), 384-384.e1. <https://doi.org/10.5694/mja2.50571>
7. Tangermann G. F  r Obdachlose wird die Pandemie zur Existenzfrage [The pandemic will be an existenzial crisis for homeless individuals]. Retrieved April 2, 2020, from <https://www.welt.de/politik/deutschland/article206648407/Coronavirus-Fuer-Obdachlose-wird-die-Pandemie-zur-Existenzfrage.html>
8. Kuttner K. Vom Hotel auf die Platte. *Taz* 2021. Retrieved from <https://taz.de/Unterbringung-von-Obdachlosen-in-Hamburg/!5772020/>
9. Bertram F, Heinrich F, Fr  b D, Wulff B, Ondruschka B, P  schel K, Hajek A et al. Loneliness among homeless individuals during the first wave of the covid-19 pandemic. *International Journal of Environmental Research and Public Health* 2021; 18(6), 1–10. <https://doi.org/10.3390/ijerph18063035>
10. Hajek A, Bertram F, Heinrich F, van R  th V, Ondruschka B, Kretzler B, K  nig H et al. Determinants of health care use among homeless individuals: evidence from the Hamburg survey of homeless individuals, 2021; 1–7.
11. van R  th V, K  nig HH, Bertram F, Schmiedel P, Ondruschka B, P  schel K, Hajek A et al. Determinants of health-related quality of life (HRQoL) among homeless individuals during the COVID-19 pandemic. *Public Health*, 2021. <https://doi.org/10.1016/j.puhe.2021.02.026>
12. Hajek A, Bertram F, van R  th V, Kretzler B, P  schel K, Heinrich F, K  nig H. Prevalence and Factors Associated with Fear of COVID-19 Among Homeless Individuals During the COVID-19 Pandemic: Evidence from the Hamburg Survey of Homeless Individuals. *Risk Management and Healthcare Policy*, Volume 14, 2021; 2689–2695. <https://doi.org/10.2147/RMHP.S317039>

Angaben zu m  glichen Interessenkonflikten: keine

## Literaturverzeichnis

Hamburger Ärzteblatt 09 | 2021

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

### S. 24 – 26: Fortschritte in der Therapie älterer Patienten mit AML.

Von Prof. Dr. Ahmet Elmaagacli, Dr. Anju Singh, PD Dr. Christian-Friedrich Jehn

1. Döhner H, Estey E, Grimwalde D, Amadori S, Appelbaum FR, Büchner Th et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* 2016; 129:424-447
2. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. *Blood*. 2009 Apr 30;113(18):4179-87. doi: 10.1182/blood-2008-07-172007.
3. Jehn CF, Pannenbeckers M, Klapproth A, Dahmash F, Salwender H et al. Risk factors for induction failure of standard chemotherapy with anthracycline and cytarabine in Acute Myeloid Leukemia Patients. *J Transl Sci* 2019; 6: DOI: 10.15761/JTS.1000365
4. Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K, Döhner H. German-Austrian AML Study Group. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. *Blood*. 2006 Nov 15;108(10):3280-8.
5. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. *J Clin Oncol*. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017. 77.6112.
6. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A et al. Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. *N Engl J Med*. 2009 Sep 24;361(13):1235-48. doi: 10.1056/NEJMoa0901409.
7. Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota VK. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7 + 3 or a hypomethylating agent. *Leukemia Research* 2019; 78: 45-51.
8. Rao AV. Fitness in the elderly: How to make decisions regarding acute myeloid leukemia induction. *Hematology Am Soc Hemtaol Edu Program* 2016; 2016: 339-47.
9. Tiong IS, Wei AH. New drugs creating new challenges in acute myeloid leukemia. *Genes Chromosomes Cancer*. 2019; 58:903-914. doi 10.1002/gcc.22750.
10. Hamaker ME et al. The relevance of a geriatric assessment for elderly patients with a haematological malignancy – a systematic review. *Leukemia Res* 2014; 38: 275-83.
11. Klepin HD et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for AML. *J Am Geriatrics Soc* 2011; 59: 1837-46.
12. Klepin HD et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. *Blood* 2013; 121: 4287-94.
13. Sustkova Z, Semerad L, Weinbergerova B, Mayer J. How to select older patients with acute myeloid leukemia fit for intensive treatment? *Haematological Oncology* 2020;1-11; doi org/10.1002/hon.2798.
14. Sorrow ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood*. 2005 Oct 15;106(8):2912-9. Epub 2005 Jun 30.

## Literaturverzeichnis

Hamburger Ärzteblatt 09 | 2021

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: [verlag@aekhh.de](mailto:verlag@aekhh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

15. DiNardo CD, Jonas BA, Pillarkat V, Thirman MJ, Garcia JS, Wei AH et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. *N Engl J Med* 2020; 383:617-629 DOI: 10.1056/NEJMoa2012971.
16. Wei AH, Montesinos P, Ivanov V et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. *Blood*. 2020; 135: 2137-2145.
17. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. *Blood* 2019; 133:7-17. doi.org/10.1182/blood-2018-08-868752.
18. Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R. Venetoclax: A new wave in hematocology. *Exp Hematol*. 2018; 61:10-25. Doi 10.1016/j.exhem.2018.02.002.
19. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. *N Engl J Med*. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359.
20. Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2018;19:889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.
21. Perl AE, Martinelli G, Cortes JE, Neubauer A, Ellin Berman E, Paolini S, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. *N Engl J Med* 2019; 381:1728-1740. doi: 10.1056/NEJMoa1902688.
22. DiNardo C, Schuh A, Stein E, Montesinos P, Wei A, de Botton S et al. Enasidenib plus Azacitidine significantly improves complete remission and overall response rates versus azacitidine monotherapy in mutant-IDH2 newly diagnosed acute myeloid leukemia (ND-AML). 25. virtuellen Jahreskongress der European Hematology Association (EHA) 2020, Abstract 139.
23. Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed AML. *Leukemia*. 2019 Apr 9. doi: 10.1038/s41375-019-0472-2.
24. Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D et al. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia. *Clin Cancer Res*. 2019; 25:6021-6025. doi: 10.1158/1078-0432.CCR-19-0365.
25. Cortes JE, Heidel FH, Fiedler W, Smith BD, RobaKT, Montesinos P et al. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. *J Hematol Oncol*. 2020 Jul 14;13(1):92. doi: 10.1186/s13045-020-00929-8.
26. Terao T, Minami Y. Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment. *Cells* 2019; 8:312-320. Doi: 10.3390/cells8040312.

### Angaben zu möglichen Interessenkonflikten:

#### Ahmet Elmaagacli und Christian Jehn:

Honorare: AbbVie, Pfizer, Amgen, Roche, BMS, Daichii, Novartis, Sanofi, Jazz, Kite/Gilead, Celgene

Reisekostenerstattung: Janssen, Amgen, Jazz, Daichii, Celgene, BMS, Janssen, Kite /Gilead, AbbVie

#### Anju Singh:

Honorare: Roche, BMS, Janssen, Astellas, Celgene

Reisekostenerstattung: Janssen, Amgen, Medac, Roche

## Literaturverzeichnis

Hamburger Ärzteblatt 09 | 2021

Seite 4

Weidestr. 122 b  
22083 Hamburg  
Redaktion

E-Mail: [verlag@aekeh.de](mailto:verlag@aekeh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

### S. 30 – 31: Der besondere Fall 1: Hyposmie bei Akromegalie.

Von PD Dr. Arne Böttcher, Dr. Johannes Bier, Dr. Andreas Lübke, Prof. Dr. Jörg Flitsch, Dr. Pedram Emami MBA

1. „Human PubMed Reference“. National Center for Biotechnology Information, U.S. National Library of Medicine.
2. Lee SE, Lee EH, Park H, Sung JY, Lee HW, Kang SY, Seo S, Kim BH, Lee H, Seo AN, Ahn G, Choi YL. The diagnostic utility of the GNAS mutation in patients with fibrous dysplasia: meta-analysis of 168 sporadic cases. *Hum Pathol.* 2012 Aug;43(8):1234-42. doi: 10.1016/j.humpath.2011.09.012. Epub 2012 Jan 14. PMID: 22245114.
3. Limbach AL, Lingen MW, McElherne J, Mashek H, Fitzpatrick C, Hyjek E, Mostofi R, Cipriani NA. The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma. *Head Neck Pathol.* 2020 Dec;14(4):889-898. doi: 10.1007/s12105-020-01139-x. Epub 2020 Feb 5. PMID: 32026294; PMCID: PMC7669933.
4. Stuck BA, Arzt M, Fietze I et al. Teil-Aktualisierung S3-Leitlinie Schlafbezogene Atmungsstörungen bei Erwachsenen. *Somnologie* 24, 176–208, 2020. <https://doi.org/10.1007/s11818-020-00257-6>

#### Angaben zu möglichen Interessenkonflikten:

PD Dr. Arne Böttcher erhielt Vortrags-, und Trainingszuschüsse durch Inspire Medical Systems, Nyxoah, ATI und APrevent Biotech GmbH.

Hinweis: Der Patient gab sein schriftliches Einverständnis zur Veröffentlichung seines Falls samt Bildmaterial.

### S. 32 – 33: Der besondere Fall 2: Intrakranielle Thrombektomie.

Von Prof. Dr. Axel Wetter, PD Dr. Hartmut Peter Burmeister, Dr. Christian Saß, Prof. Dr. Rudolf Töpfer

1. Fiehler J, Gerloff C. Mechanical thrombectomy in stroke. *Dtsch Arztebl Int* 2015; 112: 830–6. DOI: 10.3238/arztebl.2015.0830.
2. S2e Leitlinie zur Akuttherapie des ischämischen Schlaganfalls AWMF-Registernummer 030-046, Version 2021.
3. Adeoye O, Nyström KV, Yavagal DR et al. Recommendations for the Establishment of Stroke Systems of Care: A 2019 Update. A Policy Statement From the American Stroke Association. *Stroke.* 2019;50:e187–e210.
4. Boisseau W, Fahed R, Lapergue B et al. Predictors of Parenchymal Hematoma After Mechanical Thrombectomy. *Stroke.* 2019;50:2364–2370.

#### Angaben zu möglichen Interessenkonflikten:

Honorare:

Prof. Dr. Rudolf Töpfer: Novalos, Zambon, Forum für medizinische Fortbildung (FomF)

Dr. Christian Saß: Roche, Abbuie, FForum für medizinische Fortbildung (FomF)

Prof. Dr. Axel Wetter: Haus der Technik e.V. Essen